Humanizing Monoclonal Antibodies for Mucormycosis Treatment
Researchers have developed VX-01, a humanized monoclonal antibody designed to target mucormycosis, a severe fungal infection predominantly affecting immunocompromised individuals. VX-01 enhances the host’s immune response and prevents fungal angioinvasion, offering a promising adjunctive treatment for this often fatal disease. Mucormycosis, caused by Mucorales fungi, poses significant risks, especially to those with weakened immune systems. […]
VX-01 Monoclonal Antibody Targets Mucormycosis by Blocking Angioinvasion
Researchers have developed VX-01, a humanized monoclonal antibody designed to target mucormycosis, a severe fungal infection predominantly affecting immunocompromised individuals. VX-01 enhances the host’s immune response and prevents fungal angioinvasion, offering a promising adjunctive treatment for this often fatal disease. Mucormycosis, caused by Mucorales fungi, poses significant risks, especially to those with weakened immune systems. […]
With HHS Layoffs, What Becomes of Public Health?
This is the second in a series looking at the reduction and restructuring of federal health services and how that will affect public health and infectious disease clinical care. This past Friday, the Department of Health and Human Services (HHS) announced it was going to reduce its workforce by laying off 10,000 full-time employees, and […]
Collaborative HCV Care with Pharmacists Could Address System-Level Treatment Barriers
Meghan Morris, PhD, MPH Credit: UCSF This news was originally posed on our sister site, HCPLive.com New research is shedding light on the importance of collaborative care for facilitating community-based point-of-diagnosis hepatitis C virus (HCV) treatment initiation among high-risk, marginalized patient populations.1 In the No One Waits (NOW) trial, a longitudinal partnership with a specialized, […]
FDA Grants Marketing Authorization For First Home Test for STIs
Sexual transmitted infections (STIs) continue to be a public health concern. Along with millions of cases overall being diagnosed every year, attached to STIs is stigma and fear, which may prevent or delay people from getting tested. However, a new test looks to reduce these concerns by adding a layer of privacy with the ability […]
Top 5 Infectious Disease News Stories Week of March 22-29
FDA Approves Gepotidacin (Blujepa) for Uncomplicated Urinary Tract Infections The FDA has approved gepotidacin (Blujepa), a new oral antibiotic for treating uncomplicated urinary tract infections (uUTIs) in females aged 12 and older. This approval marks the first new class of oral antibiotics for uUTIs in nearly 30 years. GSK’s gepotidacin was shown to be non-inferior […]
Clinical Implications, Study Takeaways of Gepotidacin For Uncomplicated UTIs
Earlier this week, the FDA approved GSK’s antibiotic, gepotidacin (Blujepa). The treatment is indicated for uncomplicated urinary tract infections (UTIs) in female patients aged at least 12 years and weighing at least 40 kg, and that are caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus and Enterococcus faecalis.1 Gepotidacin is a first-in-class triazaacenaphthylene antibiotic with […]
HHS Plans a Major Downsize, Restructuring of Federal Health Agencies
The Health and Human Services (HHS) department announced yesterday it is planning on a major shakeup, reshuffling of the agencies and laying off thousands of workers. According to a statement by HHS, the restructuring will save taxpayers $1.8 billion per year. Its plan is to reduce 10,000 full-time employees, and when combined with HHS’ other […]
Pandemic Public Health Policy and Trust: Did We Lose the Latter Through the Former’s Actions?
In the second installment of our interview with Robert Hopkins Jr, MD, the medical director of the National Foundation for Infectious Diseases (NFID), he discusses some of the takeaways in how public health messaging was lost on the public, which lead to mistrust, and thus leaving open the door for disinformation and misinformation. Source link
Investigational Monoclonal Antibody for Chronic Hepatitis D Treatment Begins Clinical Trial
Redwood City, Calif-based Bluejay Therapeutics, announced yesterday it had dosed the first patient in their clinical trial, which will evaluate their monoclonal antibody, brelovitug (also known as BJT-778), for the treatment of chronic hepatitis D (CHD).1 The study, named AZURE-1, is a global, randomized clinical trial, examining brelovitug as a monotherapy for adults living with CHD […]
